Scolaris Content Display Scolaris Content Display

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 1 Adverse effects: 1. Autonomic ‐ specific ‐ orthostatic.
Figuras y tablas -
Analysis 1.1

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 1 Adverse effects: 1. Autonomic ‐ specific ‐ orthostatic.

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 2 Adverse effects: 2. Extrapyramidal effects.
Figuras y tablas -
Analysis 1.2

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 2 Adverse effects: 2. Extrapyramidal effects.

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 3 Adverse effects: 3. 'Psychic' side effects ‐ related to level of arousal.
Figuras y tablas -
Analysis 1.3

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 3 Adverse effects: 3. 'Psychic' side effects ‐ related to level of arousal.

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 4 Adverse effects: 5. Weight ‐ change (kg).
Figuras y tablas -
Analysis 1.4

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 4 Adverse effects: 5. Weight ‐ change (kg).

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 5 Leaving the study early.
Figuras y tablas -
Analysis 1.5

Comparison 1 ZUCLOPENTHIXOL vs PLACEBO (only short term), Outcome 5 Leaving the study early.

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 1 Global state: 1. Not improved (CGI).
Figuras y tablas -
Analysis 2.1

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 1 Global state: 1. Not improved (CGI).

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 2 Global state: 2. Average score (CGI, high score = poor).
Figuras y tablas -
Analysis 2.2

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 2 Global state: 2. Average score (CGI, high score = poor).

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 3 Mental state: 1. Average scores (BPRS, high score=poor).
Figuras y tablas -
Analysis 2.3

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 3 Mental state: 1. Average scores (BPRS, high score=poor).

Study

Intervention

Mean

SD

N

BPRS

Balasubramanian 1991

Zuclopenthixol

13.1

11.7

50

Balasubramanian 1991

Chlorpromazine

12.9

9.3

44

Heikkila 1992

Zuclopenthixol

11.6

10.05

20

Heikkila 1992

Haloperidol

10.3

9.5

18

CPRS

Remvig 1987

Zuclopenthixol

6.3

5.5

22

Remvig 1987

Perphenazine

5.9

6.5

18

Figuras y tablas -
Analysis 2.4

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 4 Mental state: 2. Average scores (data skewed, high score=poor).

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 5 Adverse effects: 1. General non‐specific.
Figuras y tablas -
Analysis 2.5

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 5 Adverse effects: 1. General non‐specific.

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 6 Adverse effects: 2. Autonomic side effects.
Figuras y tablas -
Analysis 2.6

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 6 Adverse effects: 2. Autonomic side effects.

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 7 Adverse effects: 3. Extrapyramidal effects.
Figuras y tablas -
Analysis 2.7

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 7 Adverse effects: 3. Extrapyramidal effects.

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 8 Adverse effects: 4. 'Psychic' side effects ‐ related to level of arousal.
Figuras y tablas -
Analysis 2.8

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 8 Adverse effects: 4. 'Psychic' side effects ‐ related to level of arousal.

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 9 Adverse effects: 5a. Weight ‐ change (kg).
Figuras y tablas -
Analysis 2.9

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 9 Adverse effects: 5a. Weight ‐ change (kg).

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 10 Adverse effects: 5b. Weight ‐ total weight increase (kg).
Figuras y tablas -
Analysis 2.10

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 10 Adverse effects: 5b. Weight ‐ total weight increase (kg).

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 11 Leaving the study early.
Figuras y tablas -
Analysis 2.11

Comparison 2 ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term), Outcome 11 Leaving the study early.

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 1 Global state: Unchanged or worse(CGI).
Figuras y tablas -
Analysis 3.1

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 1 Global state: Unchanged or worse(CGI).

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 2 Mental state: 1. No clinical response.
Figuras y tablas -
Analysis 3.2

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 2 Mental state: 1. No clinical response.

Study

Intervention

Mean

SD

N

Notes

Mahadevan 1991

Zuclopenthixol

5.7

5.3

16

Mahadevan 1991

Sulpiride

7.0

9.3

24

Figuras y tablas -
Analysis 3.3

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 3 Mental state: 2. Average scores(BPRS, data skewed, high score=poor).

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 4 Adverse effects: 1. General ‐ reporting adverse effects (UKU‐side effect rating scale).
Figuras y tablas -
Analysis 3.4

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 4 Adverse effects: 1. General ‐ reporting adverse effects (UKU‐side effect rating scale).

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 5 Adverse effects: 2. Autonomic side effects.
Figuras y tablas -
Analysis 3.5

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 5 Adverse effects: 2. Autonomic side effects.

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 6 Adverse effects: 3. Extrapyramidal effects.
Figuras y tablas -
Analysis 3.6

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 6 Adverse effects: 3. Extrapyramidal effects.

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 7 Adverse effects: 4. 'Psychic' side effects ‐ related to level of arousal.
Figuras y tablas -
Analysis 3.7

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 7 Adverse effects: 4. 'Psychic' side effects ‐ related to level of arousal.

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 8 Adverse effects: 5. Weight ‐ change (kg).
Figuras y tablas -
Analysis 3.8

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 8 Adverse effects: 5. Weight ‐ change (kg).

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 9 Leaving the study early.
Figuras y tablas -
Analysis 3.9

Comparison 3 ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term), Outcome 9 Leaving the study early.

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 1 Global state: Unchanged or worse (CGI).
Figuras y tablas -
Analysis 4.1

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 1 Global state: Unchanged or worse (CGI).

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 2 Adverse effects: 1. General non‐specific ‐ interfering with functioning/outweighing therapeutic effect.
Figuras y tablas -
Analysis 4.2

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 2 Adverse effects: 1. General non‐specific ‐ interfering with functioning/outweighing therapeutic effect.

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 3 Adverse effects: 1. Extrapyramidal effects ‐ treatment with antiparkinsonian drug.
Figuras y tablas -
Analysis 4.3

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 3 Adverse effects: 1. Extrapyramidal effects ‐ treatment with antiparkinsonian drug.

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 4 Adverse effects: 3. 'Psychic' ‐ sedation.
Figuras y tablas -
Analysis 4.4

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 4 Adverse effects: 3. 'Psychic' ‐ sedation.

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 5 Leaving the study early ‐ by 1 week.
Figuras y tablas -
Analysis 4.5

Comparison 4 CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term), Outcome 5 Leaving the study early ‐ by 1 week.

Comparison 1. ZUCLOPENTHIXOL vs PLACEBO (only short term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Adverse effects: 1. Autonomic ‐ specific ‐ orthostatic Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.29 [0.01, 6.60]

2 Adverse effects: 2. Extrapyramidal effects Show forest plot

2

64

Risk Ratio (M‐H, Fixed, 95% CI)

5.73 [1.12, 29.34]

2.1 general ‐ extrapyramidal effects ‐ UKU side effect rating scale

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

6.07 [0.86, 43.04]

2.2 specific ‐ tremor

1

36

Risk Ratio (M‐H, Fixed, 95% CI)

5.0 [0.26, 97.37]

3 Adverse effects: 3. 'Psychic' side effects ‐ related to level of arousal Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 specific ‐ excitation

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

2.63 [0.12, 59.40]

3.2 specific ‐ sleepiness / sedation

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

2.89 [1.01, 8.30]

4 Adverse effects: 5. Weight ‐ change (kg) Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.43 [0.17, 1.11]

4.1 loss or gain of weight of 10 pounds (high change=poor)

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.43 [0.17, 1.11]

5 Leaving the study early Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.29 [0.01, 6.60]

5.1 due to adverse effects

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.29 [0.01, 6.60]

Figuras y tablas -
Comparison 1. ZUCLOPENTHIXOL vs PLACEBO (only short term)
Comparison 2. ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global state: 1. Not improved (CGI) Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 not 'mildly ill or normal'

2

114

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.55, 1.66]

1.2 unchanged or worse

7

357

Risk Ratio (M‐H, Fixed, 95% CI)

0.72 [0.53, 0.98]

2 Global state: 2. Average score (CGI, high score = poor) Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐1.30, 0.90]

3 Mental state: 1. Average scores (BPRS, high score=poor) Show forest plot

1

41

Mean Difference (IV, Fixed, 95% CI)

‐2.66 [‐9.09, 3.77]

4 Mental state: 2. Average scores (data skewed, high score=poor) Show forest plot

Other data

No numeric data

4.1 BPRS

Other data

No numeric data

4.2 CPRS

Other data

No numeric data

5 Adverse effects: 1. General non‐specific Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 rated on TESS ‐ unspecified

1

30

Risk Ratio (M‐H, Fixed, 95% CI)

1.5 [0.99, 2.27]

5.2 needing treatment with drugs not used for psychiatric disorders

1

63

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.47, 2.10]

5.3 needing treatment with hypnotics/sedative drugs

3

162

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.76, 1.56]

5.4 needing treatment with additional neuroleptic drugs

1

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.63 [0.35, 1.12]

5.5 adverse effects interfering with patient's functioning

1

63

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.64, 1.29]

6 Adverse effects: 2. Autonomic side effects Show forest plot

2

92

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.35, 2.24]

6.1 general ‐ autonomic side effects(UKU side effect rating scale)

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

2.36 [0.71, 7.85]

6.2 specific ‐ orthostatic side effects

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.11 [0.01, 1.73]

7 Adverse effects: 3. Extrapyramidal effects Show forest plot

8

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 general ‐ needing antiparkinsonian medication

6

280

Risk Ratio (M‐H, Fixed, 95% CI)

1.07 [0.86, 1.33]

7.2 general ‐ extrapyramidal effects ‐ UKU side effect rating scale

2

92

Risk Ratio (M‐H, Fixed, 95% CI)

0.78 [0.56, 1.09]

7.3 specific ‐ akathisia

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

2.06 [0.60, 7.07]

7.4 specific ‐ hypokinesia / akinesia

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

0.76 [0.30, 1.93]

7.5 specific ‐ dystonia

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

0.30 [0.01, 6.94]

7.6 specific ‐ tremor

2

85

Risk Ratio (M‐H, Fixed, 95% CI)

0.71 [0.29, 1.73]

8 Adverse effects: 4. 'Psychic' side effects ‐ related to level of arousal Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

8.1 general ‐ 'psychic' side effects(UKU side effect rating scale)

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

1.77 [0.79, 3.95]

8.2 specific ‐ asthenia

1

49

Risk Ratio (M‐H, Fixed, 95% CI)

1.77 [0.50, 6.28]

8.3 specific ‐ excitation

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.62 [0.07, 5.47]

8.4 specific ‐ sleepiness / sedation

2

92

Risk Ratio (M‐H, Fixed, 95% CI)

1.57 [0.93, 2.65]

9 Adverse effects: 5a. Weight ‐ change (kg) Show forest plot

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.50 [0.20, 1.23]

9.1 loss or gain of weight of 10 pounds (high change=poor)

1

43

Risk Ratio (M‐H, Fixed, 95% CI)

0.50 [0.20, 1.23]

10 Adverse effects: 5b. Weight ‐ total weight increase (kg) Show forest plot

1

83

Mean Difference (IV, Fixed, 95% CI)

‐1.89 [‐7.89, 4.11]

11 Leaving the study early Show forest plot

10

488

Risk Ratio (M‐H, Fixed, 95% CI)

0.71 [0.52, 0.97]

11.1 any reason

8

424

Risk Ratio (M‐H, Fixed, 95% CI)

0.70 [0.51, 0.95]

11.2 due to adverse effects

2

64

Risk Ratio (M‐H, Fixed, 95% CI)

1.28 [0.18, 8.82]

Figuras y tablas -
Comparison 2. ZUCLOPENTHIXOL vs OTHER TYPICAL ANTIPSYCHOTICS (only short term)
Comparison 3. ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global state: Unchanged or worse(CGI) Show forest plot

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

1.30 [0.80, 2.11]

2 Mental state: 1. No clinical response Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 not achieving clinical response (at least 20% reduction in the total PANSS score)

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

1.39 [0.92, 2.10]

2.2 not achieving clinical response for the total PANSS ‐ derived BPRS score

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

1.23 [0.82, 1.86]

3 Mental state: 2. Average scores(BPRS, data skewed, high score=poor) Show forest plot

Other data

No numeric data

4 Adverse effects: 1. General ‐ reporting adverse effects (UKU‐side effect rating scale) Show forest plot

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.87, 1.11]

5 Adverse effects: 2. Autonomic side effects Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 specific ‐ gastrointestinal side effects

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

0.15 [0.01, 2.82]

5.2 specific ‐ anticholinergic side effects

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.29, 2.63]

5.3 specific ‐ orthostatic reaction

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

0.35 [0.01, 8.36]

5.4 specific ‐ headache

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.07, 16.25]

5.5 specific ‐ hypersalivation

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.07, 16.25]

5.6 specific ‐ dizziness

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.16, 7.10]

6 Adverse effects: 3. Extrapyramidal effects Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 general ‐ extrapyramidal side effects(ESRS)

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

1.5 [0.92, 2.44]

6.2 general ‐ needing antiparkinsonian medication

1

98

Risk Ratio (M‐H, Fixed, 95% CI)

1.92 [1.12, 3.28]

6.3 specific ‐ hypokinesia

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.07, 16.25]

6.4 specific ‐ hyperkinesia

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

3.16 [0.13, 75.20]

6.5 specific ‐ rigor

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

2.11 [0.20, 22.29]

6.6 specific ‐ tremor

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

2.11 [0.20, 22.29]

6.7 specific ‐ akathisia

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.07, 16.25]

7 Adverse effects: 4. 'Psychic' side effects ‐ related to level of arousal Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 specific ‐ drowsiness

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.29, 3.91]

7.2 specific ‐ stimulation

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

0.66 [0.24, 1.83]

7.3 specific ‐ confusion

1

74

Risk Ratio (M‐H, Fixed, 95% CI)

0.35 [0.01, 8.36]

8 Adverse effects: 5. Weight ‐ change (kg) Show forest plot

1

40

Mean Difference (IV, Fixed, 95% CI)

‐1.60 [‐10.06, 6.86]

9 Leaving the study early Show forest plot

2

159

Risk Ratio (M‐H, Fixed, 95% CI)

1.48 [0.98, 2.22]

Figuras y tablas -
Comparison 3. ZUCLOPENTHIXOL vs ATYPICAL ANTIPSYCHOTICS (only short term)
Comparison 4. CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global state: Unchanged or worse (CGI) Show forest plot

3

131

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.76, 1.52]

2 Adverse effects: 1. General non‐specific ‐ interfering with functioning/outweighing therapeutic effect Show forest plot

3

131

Risk Ratio (M‐H, Fixed, 95% CI)

0.74 [0.46, 1.21]

3 Adverse effects: 1. Extrapyramidal effects ‐ treatment with antiparkinsonian drug Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

1.4 [0.67, 2.94]

4 Adverse effects: 3. 'Psychic' ‐ sedation Show forest plot

1

57

Risk Ratio (M‐H, Fixed, 95% CI)

0.19 [0.02, 1.55]

5 Leaving the study early ‐ by 1 week Show forest plot

2

29

Risk Ratio (M‐H, Fixed, 95% CI)

5.0 [0.27, 92.62]

Figuras y tablas -
Comparison 4. CIS‐(Z) ZUCLOPENTHIXOL vs CIS(Z)+TRANS(E) FORM OF ZUCLOPENTHIXOL (only short term)